San Diego's Seawolf Therapeutics Raises $100M From Versant Ventures and Big Pharma Backers for DNA Medicines
Eli Lilly, CRISPR Therapeutics and Novartis's venture arm are among the investors betting on redosable, non-viral DNA therapies.
Seawolf Therapeutics, a San Diego biotech developing DNA-based medicines, has raised $100 million from a roster of venture firms and pharmaceutical companies, BioPharma Dive reported on November 16, 2026.
Who Invested
Versant Ventures, which led Seawolf's seed round, also took part in a Series A alongside other investors. The $100 million total spans those financings. MPM BioImpact and Alexandria Venture Investments participated, and Eli Lilly, CRISPR Therapeutics and Novartis's venture arm also contributed. Versant managing director Tom Woiwode chairs Seawolf's board.
Woiwode said the company is now showing that DNA can drive strong, long-lasting protein expression.
What Seawolf Does
Seawolf's TRIDENT platform packages engineered DNA, designed not to trigger an immune response, inside a proprietary lipid nanoparticle. An additional component helps carry the DNA into the cell nucleus, where it instructs cells to produce therapeutic proteins.
The company's argument is that this combines the delivery advantages of RNA-based lipid nanoparticle drugs with the longer-lasting protein expression of DNA. Because it does not rely on viruses to deliver genetic material, Seawolf says its therapies can be given more than once, which would let doctors adjust or top up a dose over time. Viral gene therapies generally cannot be redosed because patients develop immunity to the delivery vector.
The company says the platform is designed to work across both rare and more common diseases. Seawolf highlights redosing as a key differentiator, describing it as the ability to fine-tune or supplement treatment through repeated administration.
Pipeline and Partnerships
Seawolf's lead program targets metabolic disease. The company says it has data in primate and mouse models across metabolic and rare diseases, and that primate studies showed potent, durable and safe results.
It also has a multi-target research collaboration and exclusive license with Sanofi focused on bleeding disorders and other undisclosed indications. Under that deal, Seawolf could receive up to $1.2 billion in milestone payments plus tiered royalties.
What the Money Is For
CEO Elizabeth Alcamo said the financing positions the company to advance its lead metabolic program and continue its work with Sanofi, adding that Seawolf is "well-positioned to execute on our next stage of growth."
Why It Matters
The raise lands in a tougher year for metabolic-focused startups. According to BioPharma Dive's data, companies in the space have raised about $740 million in 2026 from active biotech venture firms, down from roughly $1.3 billion in 2025 and $1.6 billion in 2024.
A nine-figure total with Lilly, a major player in obesity and diabetes drugs, on the cap table is a strong signal. If Seawolf can show that non-viral DNA can deliver durable, redosable protein expression in people, it would open a middle path between short-lived RNA medicines and one-shot viral gene therapies.
Source
BioPharma Dive — "Big-name investors pour $100M into DNA therapeutics developer Seawolf"